ReviewMicrobiology spectrum2019
Pathogenicity of Enterococci.
Review in Microbiology spectrum, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 296 papers, 4 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
296 citing papers in PubMed, 4 syntheses or guidelines pooled it, 479 citations in OpenAlex.
- Association of virulence genes with biofilm formation in clinical Enterococcus faecalis isolates: a systematic review and meta-analysis.Archives of microbiology · 2026Pooled it
- The global prevalence of biofilm-forming Enterococcus faecalis in clinical isolates: a systematic review and meta-analysis.BMC infectious diseases · 2025Pooled it
- Global trends in antimicrobial resistance ofFrontiers in pharmacology · 2025Pooled it
- Gut Bacteroides act in a microbial consortium to cause susceptibility to severe malaria.Nature communications · 2023Pooled it
- The impact of an oral purified microbiome therapeutic on the gastrointestinal microbiome.Nature medicine · 2026Trial
- Impact of mechanical bowel preparation on the gut microbiome of patients undergoing left-sided colorectal cancer surgery: randomized clinical trial.The British journal of surgery · 2024Trial
- Impact of a Purified Microbiome Therapeutic on Abundance of Antimicrobial Resistance Genes in Patients With Recurrent Clostridioides difficile Infection.Clinical infectious diseases : an official publication of the Infectious Diseases Society of America · 2024Trial
- Clonal diversity, virulence factors and antibiotic resistance genes ofOne health (Amsterdam, Netherlands) · 2026Article
- The biliary microbiome in symptomatic cholelithiasis: a prospective comparison across distinct bacterial niches.BMC microbiology · 2026Observational
- Structural and genetic dissection of RNA-guided gene repression by TnpB-derived transcription factors.bioRxiv : the preprint server for biology · 2026Article
- Evaluation of resistance mechanisms and susceptibility testing in Enterococcus spp.: implications of vancomycin-variable isolates and optrA-mediated resistance.European journal of clinical microbiology & infectious diseases : official publication of the European Society of Clinical Microbiology · 2026Article
- Purine and pyrimidine-based bacterial cyclic dinucleotides egress the phagosome and activate the innate immune sensor STING.Immunity · 2026Article
- Article
- PK/PD study of vancomycin in enterococcal infections: efficacy and safety assessment under the guidance of TDM.Microbiology spectrum · 2026Observational
- Characterization ofPHAGE (New Rochelle, N.Y.) · 2026Article
- Tunable TriPcides suppress virulence factor secretion duringScience advances · 2026Article
- Characterization of a novel cell wall-associated nucleotidase of Enterococcus faecalis that degrades extracellular c-di-AMP.PLoS pathogens · 2026Article
- Article
- Genomic investigation of the vancomycin-resistant Enterococcus faecium in a tertiary hospital in China.Antimicrobial resistance and infection control · 2026Article
- Review
236 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 1 institution in 1 country.
Funding
Abstract
Enterococci are unusually well adapted for survival and persistence in a variety of adverse environments, including on inanimate surfaces in the hospital environment and at sites of infection. This intrinsic ruggedness undoubtedly played a role in providing opportunities for enterococci to interact with other overtly drug-resistant microbes and acquire additional resistances on mobile elements. The rapid rise of antimicrobial resistance among hospital-adapted enterococci has rendered hospital-acquired infections a leading therapeutic challenge. With about a quarter of a genome of additional DNA conveyed by mobile elements, there are undoubtedly many more properties that have been acquired that help enterococci persist and spread in the hospital setting and cause diseases that have yet to be defined. Much remains to be learned about these ancient and rugged microbes, particularly in the area of pathogenic mechanisms involved with human diseases.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.